Dermata Therapeutics Q3 net loss narrows as R&D expenses fall

Overview

• Dermata reports Q3 net loss of $1.7 mln, with decreased R&D expenses

• Company shifts focus to OTC dermatology products, plans 2026 product launch

• Cash reserves increased to $4.7 mln, expected to fund operations into Q2 2026

Outlook

• Dermata plans to launch its first OTC acne kit in mid-2026

• Company expects to fund operations into Q2 2026 with current cash

• Dermata working on brand identity for OTC product portfolio

Result Drivers

• STRATEGIC PIVOT - Dermata shifed focus to OTC skincare to meet consumer demand for accessible dermatologic solutions

• Research and development expenses were $0.5 million for the quarter ended September 30, 2025, compared to $2.4 million for the quarter ended September 30, 2024.

• CLINICAL SUCCESS - Positive results from XYNGARI Phase 3 trial support OTC product development

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Dermata Therapeutics Inc is $10.00, about 68.6% above its November 13 closing price of $3.14

Press Release: ID:nACSfhXf4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)